Aspheric ablation: good for hyperopic presbyopes

Article

Aspheric ablation is a good surgical option for enhancing near vision in hyperopic presbyopes.

Aspheric ablation is a good surgical option for enhancing near vision in hyperopic presbyopes, according to Marc Lafontaine and colleagues from the Canadian multicentre LASIK trial of aspheric treatments for the correction of hyperopic presbyopia.

A total of 93 hyperopic presbyopic eyes that underwent aspheric ablation were included in the study and used as the basis for predictive factors. Mean preoperative sphere was 1.67 D and the mean cylinder was 0.43 D. Pre- and postoperative subjective questionnaires were handed-out to each subject.

All patients achieved simultaneous 20/25 distance vision and J3 vision at 12-months follow-up. Patient satisfaction was good and spectacle independence was achieved and maintained in more than half of subjects.

Predictive factors of good outcomes include patients requiring glasses for distance vision preoperatively, hyperopic refractive error to appreciate a three line or more improvement and three to six months for neural adaptation to realise the benefit of correction.

The study found that aspheric ablation is a good surgical option for enhancing near vision in hyperopic presbyopes and that patient selection is a key factor in predicting good refractive outcomes and satisfaction.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.